Clinical Trials Logo

Cirrhosis Due to Hepatitis C clinical trials

View clinical trials related to Cirrhosis Due to Hepatitis C.

Filter by:
  • None
  • Page 1

NCT ID: NCT05832229 Recruiting - Cirrhosis Clinical Trials

Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States

LCN RESCU
Start date: October 11, 2023
Phase: Phase 2
Study type: Interventional

This is a double-blind, phase 2 study to evaluate safety and efficacy of rosuvastatin in comparison to placebo after 2 years in patients with compensated cirrhosis.

NCT ID: NCT05740358 Recruiting - Cirrhosis Clinical Trials

Liver Cirrhosis Network Cohort Study

LCN-C
Start date: November 14, 2022
Phase:
Study type: Observational

Liver Cirrhosis Network (LCN) Cohort Study is an observational study designed to identify risk factors and develop prediction models for risk of decompensation in adults with liver cirrhosis. LCN Cohort Study involves multiple institutions and an anticipated 1200 participants. Enrolled participants will have study visits every 6 months (180 days), with opportunities to complete specific visit components via telehealth or remotely. Visits will include collection of questionnaire data and the in-person visits will include questionnaires, physical exams, imaging, and sample collection.

NCT ID: NCT04543643 Not yet recruiting - Clinical trials for Gastroesophageal Varices

Endoscopic and Microbiological Assessment of the Effect of Carvedilol Combined With Berberine on GOV in Cirrhosis

CABER
Start date: November 1, 2021
Phase: Phase 3
Study type: Interventional

Carvedilol has been shown to be more potent in decreasing portal hypertension to propranolol. A lot of studies have shown that the imbalance of flora and the progress of portal hypertension are mutually causal. Berberine can regulate the intestinal flora.In this study, we evaluated the effect of carvedilol and berberine on reducing portal vein pressure by observing the changes of endoscopy,endoscopic ultrasonography and intestinal flora.